close

Agreements

1 202 203 204
Number of results: 4070

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2010-01-06 Amsterdam Molecular Therapeutics (The Netherlands) - consortium led by Institut Pasteur (France) adeno-associated viral 5 (AAV5) gene therapy Sanfilippo B (rare autosomal recessive lysosomal storage disease, which manifests in young children)

Development
Manufacturing
Production

Rare diseases Development agreement
0201-10-06 Horizon Discovery (UK) Haplogen Genomics (Austria) CRISPR/Cas9 human haploid cell line generation service and human haploid knock-out cell lines catalog

distribution

Technology - Services Distribution agreement
0000-00-00 ViiV Healthcare (UK - USA) the Medicines Patent Pool Tivicay® (dolutegravir) HIV1-infection

collaboration

Infectious diseases Collaboration agreement
0000-00-00 Ipsen (France)

nomination

Nomination
0000-00-00 Santen Pharmaceutical (Japan) new European Head Quarters in Geneva

opening of new premises

Ophtalmological diseases Opening of new premises
0000-00-00 Bluebird bio (USA - MA)

resignation

Resignation
0000-00-00 Ascendis Pharma (Denmark)

nomination

Nomination
0000-00-00 Macrogenics (USA - MD) Synthon (The Netherlands) MGC018,

licensing

development

Cancer - Oncology - Technology - Services Licensing agreement
0000-00-00 Macrogenics (USA - MD) Synthon (The Netherlands) MGC018,

licensing

development

Cancer - Oncology - Technology - Services Licensing agreement
0000-00-00 Loxo Oncology (USA - CT) Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland) companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib Cancer - Oncology - Diagnostic Establishment of a new subsidiary in the EU